Regulatory
BioSyent Announces Health Canada Approval of Thyconvi(TM) (levothyroxine oral solution)
BioSyent enters endocrinology with sole-source liquid levothyroxine — a niche launch, but the upside hinges on Tibella/FeraMAX still doing the heavy lifting.
Executive Summary
- Health Canada approved Thyconvi (levothyroxine sodium 20 mcg/mL oral solution) for treatment of hypothyroidism and pituitary TSH suppression.
- BioSyent Pharma Inc. (wholly-owned subsidiary) holds exclusive Canadian rights to register, market, sell, and distribute.
- Product is positioned as the first and only oral liquid levothyroxine in Canada — targeting patients who struggle with solid-dose forms (pediatric, geriatric, dysphagia, dose-titration cases).
- Supplied as 2 × 75 mL bottles, no refrigeration required.
- Launch indicated as "in the coming months" — no revenue guidance, no pricing, no supply or manufacturing partner disclosed in the release.
- Marks BioSyent's first entry into the endocrinology therapeutic area.
Material Impact
- Positive but not transformative. Levothyroxine is one of the most-prescribed drugs in Canada, but the addressable subset for a liquid formulation is the minority of patients who cannot reliably take tablets. The competitive backdrop in pill form is intensely generic, so the liquid niche is precisely where BioSyent should be — but it is still a niche of a niche.
- Strategic value: opens a new therapeutic area (endocrinology) which can be leveraged for future in-licensed products. Consistent with BioSyent's playbook (in-license, register, distribute) — same model as Tibella, FeraMAX, and now the Oral Science dental channel.
- Financial value is unquantified. No partner, no upfront, no manufacturing economics, no guidance. Until the company puts a number on the launch or it shows up in Canadian pharma sales, treat the immediate P&L impact as small.
- Materiality call: this is genuinely new (regulatory milestone the market could not have priced precisely) and creates a recurring revenue stream in a new vertical, so Material - Positive — but well short of Game Changer because of the niche size and absence of disclosed economics.
- The bigger 2026 needle-mover remains the Oral Science acquisition (added $2.98M sales in March alone, ~$36M annualized run-rate of incremental revenue if Q1 is representative). Thyconvi is additive, not central.
RX · Price
Company Overview
- BioSyent is a Canadian specialty pharmaceutical company that in-licenses, registers, and distributes pharma products in Canada and select international markets. Headquarters in Mississauga, ON.
- Core legacy franchises: FeraMAX (iron supplements) and Tibella (tibolone for menopausal hormone therapy — assets acquired in 2024). Tibella generated $2.4M in international sales in 2025.
- New oral health segment: Oral Science Inc. (Brossard, QC), acquired in March 2026, distributes dental hygiene products to dental clinics — diversified channel from BioSyent's existing pharmacy/retail pharma channel.
- New endocrinology vertical: Thyconvi (the subject news), launch expected later in 2026.
- Insecticide line: small and shrinking (Q1 2026 sales -58% YoY at $120k), de minimis to the thesis.
More from BioSyent Inc.
May 14, 2026 · 18:00